A study in a rat initiation-promotion bladder tumour model demonstrated no promoter/progressor potential of dapagliflozin

Regulatory Toxicology and Pharmacology

Volumn 103, Issue , 2019, Pages 166-173

  Billger, Martin ^a   Kirk, Jason ^b   Chang, Jane ^b   Bédard, Agathe ^c   Attalla, Bassem ^c   Haile, Solomon ^c   Söderberg, Magnus ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

^c CHARLES RIVER LABORATORIES   (United States)

Author keywords

Bladder cancer; Carcinogenicity; Dapagliflozin; N Butyl N (4 hydroxybutyl) nitrosamine (BBN); Rat; Sodium glucose cotransporter 2 (SGLT2); Transitional cell carcinoma (TCC); Tumour initiator; Tumour progressor; Tumour promoter

Indexed keywords

DAPAGLIFLOZIN; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; URACIL; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG FORMULATION; DRUG SAFETY; HISTOPATHOLOGY; INCIDENCE; MALE; MAXIMUM CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; TUMOR INVASION; VALIDATION STUDY; ANIMAL; BLADDER TUMOR; CHEMICALLY INDUCED; DISEASE MODEL; DOSE RESPONSE; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; BENZHYDRYL COMPOUNDS; BUTYLHYDROXYBUTYLNITROSAMINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSIDES; MALE; RATS; RATS, SPRAGUE-DAWLEY; URINARY BLADDER NEOPLASMS;

EID: 85060858934     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2019.01.031     Document Type: Article

References (16)

1. Baylis, C., Corman, B., The aging kidney: insights from experimental studies. J. Am. Soc. Nephrol. 9:4 (1998), 699–709.
2. Cheng, L., MacLennan, G.T., Lopez-Beltran, A., Histologic grading of urothelial carcinoma: a reappraisal. Hum. Pathol. 43:12 (2012), 2097–2108, 10.1016/j.humpath.2012.01.008.
3. FARXIGA® (dapagliflozin) tablets product label. FDA Approved Drug Products, NDA 202293, 10/20/2017. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202293s012lbl.pdf (Last accessed Oct 25 2018).
4. Frazier, K.S., Seely, J.C., Hard, G.C., Betton, G., Burnett, R., Nakatsuji, S., Nishikawa, A., Durchfeld-Meyer, B., Bube, A., Proliferative and nonproliferative lesions of the rat and mouse urinary system. Toxicol. Pathol. 40:4_Suppl. l (2012), 14S–86S, 10.1177/0192623312438736.
5. Fukushima, S., Murasaki, G., Hirose, M., Nakanishi, K., Hasegawa, R., Ito, N., Histopathological analysis of preneoplastic changes during N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder carcinogenesis in rats. Acta Pathol. Jpn. 32:2 (1982), 243–250.
6. Fukushima, S., Tamano, S., Shibata, M.A., Kurata, Y., Hirose, M., Ito, N., The role of urinary pH and sodium ion concentration in the promotion stage of two-stage carcinogenesis of the rat urinary bladder. Carcinogenesis 9:7 (1988), 1203–1206.
7. Hicks, R.M., Effects of promoters on incidence of bladder cancer in experimental animal models. Environ. Health Perspect. 50 (1983), 37–49.
8. Ito, N., Fukushima, S., Promotion of urinary bladder carcinogenesis in experimental animals. Exp. Pathol. 36:1 (1989), 1–15.
9. Lubet, R.A., Fischer, S.M., Steele, V.E., Juliana, M.M., Desmond, R., Grubbs, C.J., Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers. Int. J. Canc. 123:10 (2008), 2254–2259, 10.1002/ijc.23765.
10. Obermeier, M., Yao, M., Khanna, A., Koplowitz, B., Zhu, M., Li, W., Humphreys, W.G., In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab. Dispos. 38:3 (2010), 405–414, 10.1124/dmd.109.029165 %.
11. Ptaszynska, A., Cohen, S.M., Messing, E.M., Reilly, T.P., Johnsson, E., Johnsson, K., Assessing bladder cancer risk in type 2 diabetes clinical trials: the dapagliflozin drug development program as a ‘case study. Diabetes Ther 6:3 (2015), 357–375, 10.1007/s13300-015-0128-9.
12. Reilly, T.P., Graziano, M.J., Janovitz, E.B., Dorr, T.E., Fairchild, C., Lee, F., Chen, J., Wong, T., Whaley, J.M., Tirmenstein, M., Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus. Diabetes Ther 5:1 (2014), 73–96, 10.1007/s13300-014-0053-3.
13. Shirai, T., Tagawa, Y., Fukushima, S., Imaida, K., Ito, N., Strong promoting activity of reversible uracil-induced urolithiasis on urinary bladder carcinogenesis in rats initiated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res. 47:24 Pt 1 (1987), 6726–6730.
14. Tirmenstein, M., Janovitz, E., Dorr, T., Song, Y., Chen, S.J., Granaldi, K., Chadwick, K.D., Mangipudy, R., Graziano, M., Attalla, B., Haile, S., Czajkowski, M., Foster, J.R., Bergholm, A.M., Billger, M., Söderberg, M., Evaluation of uracil, sodium ascorbate, and rosiglitazone as promoters of urinary bladder transitional cell carcinomas in male sprague-dawley rats. Toxicol. Pathol. 46:2 (2018), 147–157, 10.1177/0192623318756004.
15. Vasconcelos-Nóbrega, C., Colaço, A., Lopes, C., Oliveira, P.A., BBN as an Urothelial Carcinogen., 26(4), 2012, 727–739.
16. Wiviott, S.D., Raz, I., Bonaca, M.P., Mosenzon, O., Kato, E.T., Cahn, A., Sabatine, M.S., Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. 2018, 10.1056/NEJMoa1812389 0(0), null.